CSI and Aerolase to Codevelop Laser Atherectomy Technology

 

July 31, 2018—Cardiovascular Systems, Inc. (CSI) announced that it has signed an agreement with Aerolase Corporation to codevelop a new laser atherectomy device for treating multiple forms of arterial disease. The collaboration seeks to improve the care of patients with peripheral arterial disease and in-stent restenosis.

Aerolase’s laser technology is currently cleared by the FDA for dermatology and medical aesthetic uses. Under the terms of the agreement, CSI made an equity investment of an undisclosed value in Aerolase and will make additional equity investments as development milestones are met.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.